英文摘要 |
The development of biologics indicates substantial progress for treating autoimmune and rheumatic diseases. Subcutaneous TNF-α blockers are frequently used in Taiwan. Intravenous biologics include IL-6 receptor blockers, T-cell costimulatory modulators, and B cell target therapy. Overall, biologics entail numerous challenges, such as infection events, HBV reactivation, and the possibility of increasing risk for cancer development. Continual monitoring and infection prevention are crucial among patients who use biologics to maximize drug effects. |